- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07828444
New Zealand Blackcurrant and Recovery in Elite Taekwondo (NZBC-TAE)
Effects of New Zealand Blackcurrant Extract Supplementation on Muscle Damage, Oxidative Stress, and Inflammatory Markers Following High-Intensity Training in Elite Taekwondo Athletes
This randomized, double-blind, placebo-controlled trial evaluated the effects of short-term supplementation with anthocyanin-rich New Zealand blackcurrant (NZBC) extract on exercise-induced muscle damage, oxidative stress, antioxidant status, inflammatory responses, and perceived muscle soreness in elite male taekwondo athletes.
Thirty national-level male taekwondo athletes were enrolled and randomly assigned in a 1:1 ratio to receive either NZBC extract (CurraNZ®, UK; 600 mg/day providing approximately 210 mg anthocyanins) or a matched placebo for 7 days. Blood samples and muscle soreness ratings were collected at baseline, immediately after exercise, 24 hours after exercise, and after 7 days.
The primary outcome was plasma creatine kinase (CK). Secondary outcomes included reactive oxygen species (ROS), total antioxidant capacity (TOAC), protein carbonyls, inflammatory cytokines (IL-6, TNF-α, and IL-10), and perceived muscle soreness assessed using a visual analog scale (VAS).
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). Written informed consent was obtained from all participants.
Study Overview
Status
Detailed Description
High-intensity, impact-based sports such as taekwondo involve substantial mechanical and metabolic demands that may contribute to exercise-induced muscle damage, oxidative stress, inflammatory responses, and delayed recovery. Nutritional strategies capable of modulating these physiological responses may therefore be relevant for athletes exposed to repeated high-intensity training.
New Zealand blackcurrant (Ribes nigrum L.) is rich in anthocyanins and other polyphenolic compounds with antioxidant and anti-inflammatory properties. Previous studies involving endurance and intermittent exercise have investigated the potential effects of blackcurrant supplementation on oxidative stress, vascular responses, exercise performance, and recovery. However, evidence in elite combat-sport athletes remains limited.
The objective of this randomized controlled trial was to determine whether 7 days of standardized NZBC extract supplementation influenced biochemical markers of muscle damage, oxidative stress, antioxidant status, inflammatory cytokines, and perceived muscle soreness following repeated high-intensity training in elite male taekwondo athletes.
It was hypothesized that NZBC supplementation would attenuate exercise-associated elevations in plasma creatine kinase and reactive oxygen species, increase total antioxidant capacity, and modulate inflammatory cytokine responses, including IL-6, TNF-α, and IL-10.
The study used a randomized, double-blind, placebo-controlled, parallel-group design and was conducted at the Atik Ali Sports Club in Istanbul, Türkiye, between December 2023 and June 2024. Thirty elite male taekwondo athletes were enrolled and randomly allocated in a 1:1 ratio to receive either NZBC extract or placebo.
Participants assigned to the intervention group received 600 mg/day of New Zealand blackcurrant extract (CurraNZ®, UK), providing approximately 210 mg of anthocyanins, for 7 consecutive days. Participants assigned to the control group received a visually matched maltodextrin placebo. Randomization, allocation concealment, and blinding procedures were maintained throughout the intervention and until database lock.
Blood samples were collected at baseline, immediately following exercise, 24 hours after exercise, and after 7 days. Biochemical outcomes included plasma creatine kinase, reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, and TNF-α. Biomarkers were assessed using commercially available laboratory assay kits. Perceived muscle soreness was evaluated using a visual analog scale. Dietary intake and anthropometric characteristics were also assessed.
The primary outcome was the change in plasma creatine kinase. Secondary outcomes included reactive oxygen species, total antioxidant capacity, protein carbonyls, IL-6, IL-10, TNF-α, and perceived muscle soreness.
Statistical analyses were conducted using R version 4.3.1. Data distribution was assessed using the Shapiro-Wilk test, and homogeneity of variance was evaluated using Levene's test. Between-group comparisons were planned using independent-samples t-tests or Mann-Whitney U tests, as appropriate. Longitudinal changes were evaluated using repeated-measures analysis of variance, including group, time, and group × time interaction effects. Greenhouse-Geisser corrections were applied where assumptions of sphericity were not met. Sensitivity analyses were conducted using linear mixed-effects models. Statistical significance was defined as a two-tailed alpha level of 0.05.
The study was approved by the Biruni University Clinical Research Ethics Committee (No. 2015-KAEK-80-23-33; December 22, 2023). All participants provided written informed consent before participation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tuzla
-
Istanbul, Tuzla, Turkey (Türkiye), 34000
- Okan university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male national-level taekwondo athletes actively training and competing
- Age between 18 and 35 years
- Free from any chronic disease, metabolic disorder, or recent musculoskeletal injury
- Not using antioxidant, anti-inflammatory, or ergogenic supplements within the last 4 weeks
- Willing to maintain regular diet and training schedule during the study period
- Provided written informed consent
Exclusion Criteria:
- Female athletes
- Presence of chronic illness, injury, or infection
- Use of antioxidant or anti-inflammatory supplements in the 4 weeks prior to enrollment
- Dietary habits incompatible with the intervention (e.g., high anthocyanin intake from other sources)
- Failure to complete all study visits or provide required blood samples
- Withdrawal of consent at any time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: New Zealand Blackcurrant Extract (NZBC)
Participants received New Zealand blackcurrant extract capsules (CurraNZ®, Healthspan Elite, UK) for 7 days. The daily dose was 600 mg (two 300 mg capsules, morning and evening), providing approximately 210 mg anthocyanins per day. |
Standardized anthocyanin-rich blackcurrant extract administered orally at 600 mg/day (two 300 mg capsules) for 7 consecutive days. Each capsule contained natural polyphenolic compounds standardized to ~35% anthocyanins. |
|
Placebo Comparator: Placebo
Participants received placebo capsules identical in appearance to the NZBC capsules, containing maltodextrin. The placebo was administered orally twice daily for 7 days. |
Two identical capsules containing maltodextrin, taken daily for 7 days (morning and evening), matching the NZBC supplementation schedule. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in plasma Creatine Kinase (CK) concentration
Time Frame: Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Plasma creatine kinase (CK) activity measured via ELISA assay as a biomarker of exercise-induced muscle damage. The outcome represents the change in CK levels from baseline to 24 h and 7 d after repeated high-intensity training sessions. |
Baseline, immediately post-exercise, 24 hours, and 7 days after training
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Reactive Oxygen Species (ROS) levels
Time Frame: Baseline, immediately post-exercise, 24 hours, and 7 days
|
ROS concentrations measured by ELISA to assess oxidative stress response following high-intensity training. |
Baseline, immediately post-exercise, 24 hours, and 7 days
|
|
Change in Total Antioxidant Capacity (TOAC)
Time Frame: Baseline, 24 hours, and 7 days
|
Total antioxidant capacity determined spectrophotometrically using commercial assay kits (Sunredbio, China). Reflects systemic antioxidant defense. |
Baseline, 24 hours, and 7 days
|
|
Change in Inflammatory Cytokines (IL-6, TNF-α, IL-10)
Time Frame: Baseline, 24 hours, and 7 days
|
Serum IL-6, TNF-α, and IL-10 quantified by ELISA to evaluate systemic inflammatory and anti-inflammatory responses to exercise and supplementation. |
Baseline, 24 hours, and 7 days
|
|
Perceived Muscle Soreness (Visual Analog Scale, VAS)
Time Frame: Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Subjective muscle soreness assessed using a 10-cm visual analog scale (VAS), where 0 = no soreness and 10 = extreme soreness. |
Baseline, 12 hours, 24 hours after each training day, and 7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hacettepe1234
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data (IPD) that underlie the results reported in this article (deidentified participant data, including baseline characteristics and outcome measures) will be made available upon reasonable request to qualified researchers.
Data will be available after publication of the main results for a period of 3 years.
Requests should be directed to the corresponding author (Assoc. Prof. Sedat Arslan, Bandirma Onyedi Eylul University; email: sarslan@bandirma.edu.tr).
No identifying participant information will be shared. Supporting documents such as the study protocol, statistical analysis plan, and informed consent form will also be provided upon request.
IPD Sharing Time Frame
Deidentified IPD and supporting documents will be available beginning 1 month after publication of the primary results and for 36 months thereafter. If publication is delayed, access will begin 12 months after database lock. Extensions may be granted upon justified request.
IPD Sharing Access Criteria
Qualified researchers with a methodologically sound proposal may request access by emailing the corresponding author (Assoc. Prof. Sedat Arslan; sarslan@bandirma.edu.tr). Requests must include a brief protocol, objectives, analysis plan, and IRB/ethics determination (if applicable). A data use agreement is required. Only deidentified IPD (baseline characteristics and prespecified outcomes) and documentation (protocol, SAP, ICF templates, analytic code) will be shared. Data will be provided via a secure institutional repository link; re-identification and commercial use are prohibited.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.